Home > News > Introgen applies to market Advexin in Europe
November 13th, 2007
Introgen applies to market Advexin in Europe
Abstract:
Introgen Therapeutics Inc. and its subsidiary, Gendux Molecular Ltd., have submitted a marketing authorization application to the European Medicines Agency for Advexin, a tumor suppressor therapy for use in the treatment of a type of cancer known as Li-Fraumeni Syndrome.
Austin-based Introgen (NASDAQ: INGN) has offices housing a clinical and regulatory development staff of about 70 in the Texas Medical Center plus a manufacturing facility nearby.
A year ago, the biotech company obtained an exclusive worldwide license to a portfolio of patents from The University of Texas M.D. Anderson Cancer Center, along with agreements to commercialize products based on the licensed technologies. Those patents are focused on the delivery of biologically active proteins, polypeptides and peptides on the nanoparticle level.
Source:
bizjournals.com
Bookmark:
| Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||